

## **3B Pharmaceuticals hosts industry symposium on radiopharmaceutical innovation alliances and supports the 6<sup>th</sup> Theranostic World Congress**

Berlin, Germany, June 10, 2022 - 3B Pharmaceuticals GmbH (3BP) is proud to be a Platinum Sponsor of the 6<sup>th</sup> Theranostics World Congress<sup>1</sup> which will be held from 24<sup>th</sup> to 26<sup>th</sup> June at the RheinMain CongressCenter Wiesbaden, Germany. The event celebrates 25 years of Peptide Receptor Radionuclide Therapy (PRRT) in Germany and provides the opportunity for mutual exchange on scientific and clinical development in Theranostics and Radiomolecular Precision Oncology.

The symposium entitled “3BP’s innovation alliances - Tailoring compounds to the needs of theranostic radiopharmaceuticals” will take place on June 25, from 09:00 am to 09:55 am CEST. Clinical and industry expert chairs and speakers will be giving insights into the translation from early development stages towards successful clinical application of 3BP’s innovative peptide-based radiopharmaceuticals.

“We are proud to witness the successful translation of our peptide tracers into clinical development and how the first patients benefit from treatment with our innovative compounds” said Ulrich Reineke, Managing Director of 3BP. “The innovation alliances with our equally enthusiastic development partners who share our passion for radiopharmaceuticals are at the core of our mission to help patients suffering from cancer indications with high medical need.”

### **Symposium & Speaker Details:**

Dr. Ulrich Reineke will give the welcome address and the symposium will be opened by Dr. Christiane Smerling outlining 3BP’s discovery engine and the partnership with Fusion Pharmaceuticals. Dr. Antoine Attinger will give an insight into how radioligands can address hypoxic tumors as a cancer treatment strategy. Dr. Lindsey Rolfe will present first data from the phase 1/2 LuMIERE study on treatment of advanced or metastatic solid tumors using <sup>177</sup>Lu-FAP-2286. The session will be chaired by Prof. Wolfgang Weber and John Carney.

The symposium is free to all conference attendees and breakfast will be provided. Speakers will be available for a Q&A session at the end of the event.

### **About 3BP**

3B Pharmaceuticals discovers and develops targeted radiopharmaceuticals providing a focused and personalized approach to the treatment of cancer. Our peptides and peptidomimetics constitute excellent tumor-specific targeting moieties and are coupled to

---

<sup>1</sup> <https://www.twc-2022.org/>

therapeutic and diagnostic radioisotopes via a chelator. As a leader in peptide discovery and optimization, 3BP has built a technology platform extending from hit identification to early clinical development.

Contact:

Dr. Christiane Smerling, Head of Nuclear Medicine & Imaging

T: +49 (30) 6392-4317

F: +49 (30) 6392-4316

[info@3b-pharma.com](mailto:info@3b-pharma.com)